SREBF1 and metabolic dysfunction-associated steatotic liver disease: Overexpression of SREBP-1c induced insulin resistance, diabetes, non-alcoholic fatty liver disease (NAFLD), and accelerated atherosclerosis in mice9, 10, 11, 12.